Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences Inc. closed 8.32% below its 52-week high of $119.96, which the company reached on March 10th.

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Gilead is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

Margaret Atwood’s chilling world of Gilead returns in The Testaments, the long-anticipated sequel to her groundbreaking novel ...

Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.

Let’s just say you wake up one morning in The Handmaid’s Tale universe, stuck inside the color-coded hellscape that is Gilead ...

The National Weather Service issued a report at 9:14 p.m. EDT on Tuesday for strong thunderstorms until 10 p.m. EDT for St.

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...